Immune checkpoint inhibitors (ICIs), which specifically target CTLA‐4 and PD‐1/PD‐L1, have demonstrated the potential to restore immune cell activity against tumor cells and mitigate immune evasion. The gene discussed is CTLA4; the disease is neoplasm.